Kevin Balthaser Aclaris Therapeutics, Inc. (ACRS) insider trading activity

Kevin Balthaser is Chief Financial Officer of Aclaris Therapeutics, Inc.. Currently has a direct ownership of 24,697 shares of ACRS, which is worth approximately $51,616. The most recent transaction as insider was on Sep 01, 2024, when has been sold 286 shares (Common Stock) at a price of $1.18 per share, resulting in proceeds of $337. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 24.7K

2.98% 3M change

59.74% 12M change

Total Value Held $51,616

Kevin Balthaser Transaction History

Date	Transaction	Value	Shares Traded	Shares Held
Sep 01 2024	SELL Payment of exercise price or tax liability	$337 $1.18 p/Share	286 Reduced 1.14%	24,697 Common Stock
Sep 01 2024	BUY Exercise of conversion of derivative security	-	1,000 Added 3.85%	24,983 Common Stock
Mar 02 2024	SELL Payment of exercise price or tax liability	$529 $1.24 p/Share	427 Reduced 1.75%	23,983 Common Stock
Mar 02 2024	BUY Exercise of conversion of derivative security	-	1,500 Added 5.79%	24,410 Common Stock
Mar 01 2024	SELL Payment of exercise price or tax liability	$1,227 $1.24 p/Share	990 Reduced 4.14%	22,910 Common Stock
Mar 01 2024	BUY Exercise of conversion of derivative security	-	3,475 Added 12.84%	23,587 Common Stock
Jan 01 2024	SELL Payment of exercise price or tax liability	$2,662 $1.05 p/Share	2,536 Reduced 11.04%	20,425 Common Stock
Jan 01 2024	BUY Exercise of conversion of derivative security	-	7,500 Added 24.62%	22,961 Common Stock
Sep 06 2023	BUY Open market or private purchase	$74,971 $7.9 p/Share	9,490 Added 38.03%	15,461 Common Stock
Sep 01 2023	SELL Payment of exercise price or tax liability	$2,251 $7.9 p/Share	285 Reduced 4.56%	5,971 Common Stock
Sep 01 2023	BUY Exercise of conversion of derivative security	-	1,000 Added 13.78%	6,256 Common Stock
Mar 03 2023	SELL Open market or private sale	$11,291 $12.63 p/Share	894 Reduced 14.54%	5,256 Common Stock
Mar 02 2023	SELL Open market or private sale	$12,290 $12.29 p/Share	1,000 Reduced 17.7%	4,650 Common Stock
Mar 02 2023	BUY Exercise of conversion of derivative security	-	1,500 Added 19.61%	6,150 Common Stock
Mar 01 2023	BUY Exercise of conversion of derivative security	-	4,950 Added 46.7%	5,650 Common Stock

Kevin Balthaser

Chief Financial Officer

Wayne, PA

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells ACRS shares.

Notify only if

Value

Insider Trading

Get notified when an Aclaris Therapeutics, Inc. insider buys or sells ACRS shares.

Notify only if

Operation

Value

Type

News

Receive news related to Aclaris Therapeutics, Inc.

Track Activities on ACRS

Account